AstraZeneca stock tanks over fears of expanding China fraud probe

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China.

The decrease marked the steepest drop for the company’s stock in a single day since March 2020, according to Bloomberg.